Breaking News
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% Upgrade now

Breaking News

UK Conservative lawmaker Burns suspended after complaints about behaviour -The Sun

Britain approves AstraZeneca's preventative COVID therapy

Stock Markets Mar 17, 2022 10:31
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
 
AZN
+1.77%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
A1ZN34
+1.58%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Pushkala Aripaka

(Reuters) -Britain's medicines regulator has approved AstraZeneca (NASDAQ:AZN)'s antibody-based COVID-19 treatment for preventing infections in adults with poor immune response, marking a major step in the fight against the pandemic as infections surge globally.

The decision to grant approval for the treatment, Evusheld, was endorsed by the government's independent scientific advisory body, Britain's Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor on Thursday.

Figures showing a global rise in COVID-19 cases could herald a much bigger problem, the World Health Organization said this week, warning nations to remain vigilant.

Although 85% of Britons over the age of 12 have been vaccinated with two doses, some immune compromised individuals or those with a history of severe adverse reactions to a vaccine may need an alternative prevention option.

"While the COVID-19 vaccines continue to be the first-line defence against COVID-19, we know that some people may not respond adequately to these vaccines,' MHRA chief June Raine said.

Vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, but Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

The therapy was found to cut the risk of developing symptomatic COVID-19 by 77% in trials, with protection lasting for at least six months after a single dose, the MHRA said.

Evusheld has been also shown to save lives and prevent disease progression when given within a week of first symptoms.

Britain and AstraZeneca currently do not have an agreement for supply of Evusheld.

AstraZeneca in a statement said it hopes to see the therapy made available to Britons "as quickly as possible".

Evusheld is under a European review and has been authorised in the United States to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

The MHRA said that the treatment, given as an intra-muscular shot, should not be administered to people infected with the COVID-causing SARS-CoV-2 virus or who have had recent exposure to someone with the virus.

However, the regulator has cautioned that there was insufficient data to evaluate fully Evusheld's effectiveness against the highly contagious Omicron variant, adding that it is liaising with AstraZeneca on that.

AstraZeneca in December said a lab study had found the treatment retained neutralising activity against Omicron.

Eli Lilly (NYSE:LLY), Regeneron and GSK some other drugmakers working on antibody-based COVID-19 therapies.

Britain approves AstraZeneca's preventative COVID therapy
 

Related Articles

Credit Suisse pays down debt to calm investors
Credit Suisse pays down debt to calm investors By Reuters - Oct 07, 2022

By John Revill ZURICH (Reuters) -Credit Suisse will buy back up to 3 billion Swiss francs ($3 billion) of debt, an attempt by the Swiss bank to show its financial muscle and...

Meta Platforms' Reels Monetization is Ramping - Citi
Meta Platforms' Reels Monetization is Ramping - Citi By Investing.com - Oct 07, 2022

By Sam Boughedda  Citi analysts released a note to investors on Friday, providing positive commentary on Meta Platforms (NASDAQ:META) and its Instagram Reels product. The analysts,...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Drake Richards
Drake Richards Mar 17, 2022 8:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Omicron is as lethal as a common cold..These drugs are not required
Steven Hughes
Steven Hughes Mar 17, 2022 8:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
for some people this is a life-changing moment.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email